Paolo Andrea Zucali

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

Federico Cappuzzo, Pasi A. Jänne, Margaret C. Skokan et al. · Annals of Oncology · 2008 · 322 citations · Full text

Medicine, Pathology, Primary Resistance +8

Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma

Giovanni Luca Ceresoli, Paolo Andrea Zucali, Adolfo Favaretto et al. · Journal of Clinical Oncology · 2006 · 293 citations

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors

Iacopo Petrini, Paul S. Meltzer, In‐Kyu Kim et al. · Nature Genetics · 2014 · 250 citations · Full text

Tumor Biology, Somatic Variant, Gtf2i Occurs +10

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer

Héctor Soto Parrà, Raffaele Cavina, F Latteri et al. · British Journal of Cancer · 2004 · 202 citations · Full text

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Paolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri et al. · Journal of Clinical Oncology · 2017 · 169 citations

Cancer Management, Thymic Carcinoma Previously, Immunology +20